NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

NextCure Inc.

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on NextCure, with a price target of $15.00. According to Tip...

Piper Sandler Keeps Their Buy Rating on NextCure (NXTC)

NextCure ( ($NXTC) ) has issued an announcement. On November 12, 2025, NextCure, Inc. entered into a securities purchase agreement with institution...

Market Cap	$21.20M	P/E Ratio	N/A
52W High	$15.74	52W Low	$2.69
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	59.6%	52W Position	64.8%
Overall Score	56	Value Score	60
Quality Score	47	Technical Score	63

EPS Current Est	$-13.73	EPS Next Est	$-8.22
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NXTC	$11.14	-2.19%	36.79K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NXTC	$11.14	-2.2%	36.79K
3
4
5
6

NXTC

NXTC

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get NextCure Inc. Data in Excel

Get NextCure Inc. Data in Excel